Device Trial Radar · NCT06731946
Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms
Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 29, 2024
Primary completion
Oct 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Yibin FangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 13, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms
Conditions
- Intracranial Arterial Aneurysm
Interventions
Flow divertingDevice
Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete aneurysm occlusion rateTime frame: 12(-3 ~ +6) months
- Favorable prognosis rateTime frame: 12(-3 ~ +6) months
- Procedure-related complication rateTime frame: 12(-3 ~ +6) months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Fourth People's Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.